Chemotherapy of chronic indeterminate Chagas disease: A novel approach to treatment

Parasitology Research

Volumn 103, Issue 3, 2008, Pages 663-669

  Bazán, Paola Carolina ^a   Lo Presti, María Silvina ^a,b,d   Rivarola, Héctor Walter ^a,b   Triquell, María Fernanda ^c   Fretes, Ricardo ^c   Fernández, Alicia Ruth ^a   Enders, Julio ^a   Paglini Oliva, Patricia ^a,b,e  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b Universidad Nacional de La Rioja   (Argentina)

^c FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^d Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^e Velez Sarsfield Clinic   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; CLOMIPRAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CHAGAS DISEASE; CHEMOTHERAPY; CHRONIC DISEASE; CONTROLLED STUDY; ECG ABNORMALITY; EXPERIMENTAL ANIMAL; HEART DISEASE; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT DURATION; TRYPANOSOMA CRUZI;

ANIMALIA; MUS; TRYPANOSOMA CRUZI;

EID: 46749088598     PISSN: 09320113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00436-008-1029-x     Document Type: Article

References (29)

1. Andrade SG, Magalhes JB, Pontes AL (1989) Therapy of the chronic phase of the experimental infection by Trypanosoma cruzi with benznidazole and nifurtimox. Rev Soc Bras Med Trop 22:113-118
2. Barioglio SR, Lacuara JL, Paglini de Oliva P (1987) Effects of clomipramine upon motility of Trypanosoma cruzi. J Parasitol 73:451-452
3. Bond CS, Zhang Y, Berriman M, Cunningham ML, Fairlamb AH, Hunter WN (1999) Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors. Structure 7:81-89
4. Bustamante JM, Rivarola HW, Fernandez AR, Enders JE, Fretes R, Palma JA, Paglini-Oliva PA (2003a) Indeterminate Chagas disease: Trypanosoma cruzi strain and reinfections are factors involved in the progression of cardiopathy. Clin Sci 104:415-420
5. Bustamante JM, Rivarola HW, Fernández AR, Enders JE, Fretes R, d'Oro G, Palma JA, Paglini-Oliva PA (2003b) Trypanosoma cruzi reinfections provoke synergistic effect and cardiac b-adrenergic receptors' dysfunction in the acute phase of experimental Chagas disease. Exp Parasitol 103:136-142
6. Bustamante JM, Rivarola HW, Palma JA, Paglini-Oliva P (2004) Electrocardiographic pattern in Trypanosoma cruzi reinfected mice. Parasitology 128:415-419
7. Coupland N, Wilson S, Nutt D (1997) Antidepressant drugs and the cardiovascular system: a comparison of tricyclics and selective serotonine reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. J Psychopharmacol 11:83-92
8. Coura JR, Castro SL (2002) A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 97:3-24
9. De Oliveira RB, Vaz ABM, Alves RO, Liarte DB, Donnici CL, Romanha AJ, Zani CL (2006) Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors. Mem Inst Oswaldo Cruz 101:169-173
10. Díaz de Toranzo EG, Castro JA, Franke de Cazzulo BM, Cazzulo JJ (1988) Interaction of benznidazole reactive metabolites with nuclear and kinetoplastic DNA, proteins and lipids from Trypanosoma cruzi. Experientia 44:880-881
11. Enders JE, Paglini P, Fernandez AR, Marco F, Palma JA (1995) Cardiac beta-receptors in experimental Chagas' disease. Rev Inst Med Trop Sao Paulo 37:59-62
12. Fabbro D, Arias ED, Streiger M, Del Barco M, Amicone N, Miglietta H (2001) Evaluación de la quimioterapia específica en infectados chagásicos adultos en fase indeterminada con más de 15 años de seguimiento. Rev Fed Argent Cardiol 30:496-503
13. Fairlamb AH (1992) Metabolism and functions of trypanothione in the kinetoplastida. Annu Rev Microbiol 46:695-729
14. Garcia S, Ramos CO, Senra JF, Vilas-Boas F, Rodrigues MM, Campos de Carvalho AC, Ribeiro Dos Santos R, Soares MB (2005) Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 49:1521-1528
15. Girones N, Cuervo H, Fresno M (2005) Trypanosoma cruzi-induced molecular mimicry and Chagas disease. Curr Trop Microbiol Immunol 296:89-123
16. Gutierrez-Correa J, Fairlamb AH, Stoppani AO (2001) Trypanosoma cruzi trypanothione reductase is inactivated by peroxidase-generated phenothiazine cationic radicals. Free Radic Res 34:363-378
17. Hyland KV, Leon JS, Daniels MD, Giafis N, Woods LM, Wang K, Engman DM (2007) Modulation of autoimmunity by treatment of an infectious disease. Infect Immun 75:3641-3650
18. Kahn MOF (2007) Trypanothione reductase: a viable chemotherapeutic target for antitrypanosomal and antileishmanial drug design. Drug Target Insights 1:129-146
19. Kierszenbaum F (2005) Where do we stand on the autoimmunity hypothesis of Chagas disease? Trends in Parasitology 21:513-516
20. Paglini-Oliva P, Fernández AR, Lacuara JL (1987) Pharmacological and contractile response of myocardium of chagasic Albino Swiss mice. Acta Physiol Pharmacol Latinoam 37:395-401
21. Rassi A, Rassi WC, Little WC (2000) Chagas heart disease. Clin Cardiol 23:883-889
22. Rivarola HW, Fernández AR, Enders JE, Fretes R, Gea S, Paglini-Oliva P (2001) Effects of clomipramine on Trypanosoma cruzi infection in mice. Trans R Soc Trop Med Hyg 95:529-533
23. Rivarola HW, Bustamante JM, Lo Presti S, Fernández AR, Enders JE, Gea S, Fretes R, Paglini-Oliva P (2005) Trypanosoma cruzi: chemotherapeutic effects of clomipramine in mice infected with an isolate obtained from an endemic area. Exp Parasitol 111:80-86
24. Romanha AJ, Alves RO, Murta SM, Silva JS, Ropert C, Gazzinelli RT (2002) Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure. J Infect Dis 186:823-828
25. Schijman AJ, Vigliano CA, Viotti RJ, Burgos JM, Brandariz S, Lococo BE, Leze MI, Armenti HA, Levin MJ (2004) Trypanosoma cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic heart disease. Am J Trop Med Hyg 70:210-220
26. Schmunis GA (2007) Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 102:75-85
27. Segura MA, Molina de Raspi E, Basombrio MA (1994) Reversibility of muscle and heart lesion in chronic Trypanosoma cruzi infected mice after late trypanocidal treatment. Mem Inst Oswaldo Cruz 89:213-216
28. Sosa Estani S, Segura E (2006) Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis 19:583-587
29. Viotti R, Vigliano C (2007) Etiological treatment of chronic Chagas disease: neglected evidence by evidence-based medicine. Expert Rev Anti Infect Ther 5:526-717